Regeneron Pharmaceuticals
REGN
972 hedge funds and large institutions have $49.6B invested in Regeneron Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 148 funds opening new positions, 368 increasing their positions, 305 reducing their positions, and 88 closing their positions.
68% more first-time investments, than exits
New positions opened: 148 | Existing positions closed: 88
21% more repeat investments, than reductions
Existing positions increased: 368 | Existing positions reduced: 305
17% more capital invested
Capital invested by funds: $42.3B → $49.6B (+$7.3B)
6% more funds holding in top 10
Funds holding in top 10: 17 → 18 (+1)
5% more funds holding
Funds holding: 924 → 972 (+48)
0.09% less ownership
Funds ownership: 85.04% → 84.95% (-0.09%)
17% less call options, than puts
Call options by funds: $1.04B | Put options by funds: $1.25B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$381M |
| 2 |
Harris Associates
Chicago,
Illinois
|
+$208M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$143M |
| 4 |
HM
HealthCor Management
New York
|
+$96.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$95.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$606M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$444M |
| 3 |
BlackRock
New York
|
-$312M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$256M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$183M |
REGN Hedge Fund Activity: Q2 2021 in Review
972 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2021, worth a combined $49.6B — up 17% from $42.3B a quarter earlier.
Buyers outnumbered sellers: 148 funds opened new REGN positions and 88 closed out — a net gain of 60 holders — while 368 added to existing stakes and 305 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $381M. The largest seller was AllianceBernstein, cutting an estimated $606M.
- 972 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2021, up from 924 in Q1 2021.
- Funds reported $49.6B of Regeneron Pharmaceuticals stock for Q2 2021, up 17% quarter-over-quarter.
- 148 funds opened new Regeneron Pharmaceuticals positions in Q2 2021 and 88 closed out, a net change of +60 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2021 was JP Morgan Chase, an estimated $381M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2021 was AllianceBernstein, an estimated $606M sold.
Based on aggregated 13F filings for Q2 2021.